Shots:
- Lynk has reported topline P-III trial data assessing zemprocitinib (12 or 24mg) vs PBO in 356 pts with mod. to sev. atopic dermatitis
- At Wk. 16, zemprocitinib (12 & 24mg) met both co-1EPs, showing superiority vs PBO in EASI-75 (+38.1% & +46.4%) & vIGA-AD 0/1 (+30.3% & +31%), & significantly improved WI-NRS4 itch response (2EP; +31.3% & +31%)
- Zemprocitinib also improved EASI-50, EASI-75, EASI-90, SCORAD, DLQI & POEM, showing showing broad lesion clearance, symptom reduction & QoL benefit, with rapid onset of action and itch relief, with rapid onset in itch relief seen by Day 1 & significant WI-NRS separation, plus EASI-75 & vIGA-AD 0/1 responses by Wk. 2
Ref: PRnewswire | Image: Lynk Pharmaceuticals | Press Release
Related News: Formation Bio Licenses Lynk Pharmaceuticals’ LNK01006 to Expand its Immunology Pipeline
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
